We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The EU Commission has granted conditional approval for use of Hansa Biopharma's Idefirix (imlifidase) to desensitise kidney transplant patients with a highly sensitised immune system.
The European Medicines Agency (EMA) recommended Idefirix is granted conditional marketing authorisation for highly sensitised patients awaiting kidney transplant.